Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy

C Andrys, L Borska, D Pohl, Z Fiala, K Hamakova, J Krejsek

. 2007 ; 298 (10) : 479-483.

Jazyk angličtina Země Německo

Perzistentní odkaz   https://www.medvik.cz/link/bmc10010204

Grantová podpora
NR8154 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Část
Zdroj

E-zdroje Online

NLK SpringerLink Journals od 1997-01-01 do 2009-03-31
ProQuest Central od 2001-02-01 do 2018-12-31
Medline Complete (EBSCOhost) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2001-02-01 do 2018-12-31

Goeckerman's therapy (GT) of psoriasis is based on daily application of pharmacy grade coal tar on affected skin with subsequent exposure to UV light. Goeckerman's therapy is still the first line therapy of psoriasis in the Czech Republic because of its low cost and long-term efficacy. Disturbances in angiogenic activity are characteristic for the immunopathogenesis of psoriasis. An abnormal spectrum of cytokines, growth factors and proangiogenic mediators is produced by keratinocytes and inflammatory cells in patients suffering from the disease. The aim of this study was to evaluate the influence of GT of psoriasis on angiogenic activities by comparing serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in 44 patients with psoriasis in peripheral blood samples collected before and after therapy. Forty otherwise healthy blood donors serve as a control group. The efficacy of GT was delineated by psoriasis area and severity index (PASI). The disease activity was significantly diminished by GT (P < 0.001). The serum levels of both VEGF and bFGF were statistically significantly correlated to PASI value in patients before the treatment by GT. The serum levels of VEGF (329.4 +/- 125.5 microg/ml) and bFGF (10.2 +/- 5.04 pg/ml) in patients before GT were significantly higher than those measured in healthy blood donors (VEGF 236.4 +/- 55.9 pg/ml, bFGF 7.3 +/- 3.7 pg/ ml). The serum levels of both VEGF and bFGF were significantly diminished by GT. The level of VEGF dropped from 329.4 +/- 125.5 pg/ml before GT to 278.5 +/- 109.9 pg/ml after GT (P = 0.0042) and the level of bFGF fell from 10.2 +/- 5.04 to 7.78 +/- 4.5 pg/ml (P = 0.019). Comparing to healthy controls, the serum level of bFGF in psoriasis patients was normalised (P = 0.5723) after GT. In contrast, the serum level of VEGF remained significantly increased in psoriasis patients after GT in comparison with healthy blood donors (P = 0.0319). In conclusion, we found that the angiogenic potential which is abnormally increased in patients with psoriasis is significantly alleviated by GT.

000      
03971naa 2200493 a 4500
001      
bmc10010204
003      
CZ-PrNML
005      
20130815101828.0
008      
100429s2007 gw e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Andrýs, Ctirad, $d 1962- $7 mzk2008430528
245    10
$a Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy / $c C Andrys, L Borska, D Pohl, Z Fiala, K Hamakova, J Krejsek
314    __
$a Department of Clinical Immunology and Allergy, School of Medicine, Charles University in Prague, Hradec Kralove, Czech Republic. andrys@lfhk.cuni.cz
520    9_
$a Goeckerman's therapy (GT) of psoriasis is based on daily application of pharmacy grade coal tar on affected skin with subsequent exposure to UV light. Goeckerman's therapy is still the first line therapy of psoriasis in the Czech Republic because of its low cost and long-term efficacy. Disturbances in angiogenic activity are characteristic for the immunopathogenesis of psoriasis. An abnormal spectrum of cytokines, growth factors and proangiogenic mediators is produced by keratinocytes and inflammatory cells in patients suffering from the disease. The aim of this study was to evaluate the influence of GT of psoriasis on angiogenic activities by comparing serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in 44 patients with psoriasis in peripheral blood samples collected before and after therapy. Forty otherwise healthy blood donors serve as a control group. The efficacy of GT was delineated by psoriasis area and severity index (PASI). The disease activity was significantly diminished by GT (P < 0.001). The serum levels of both VEGF and bFGF were statistically significantly correlated to PASI value in patients before the treatment by GT. The serum levels of VEGF (329.4 +/- 125.5 microg/ml) and bFGF (10.2 +/- 5.04 pg/ml) in patients before GT were significantly higher than those measured in healthy blood donors (VEGF 236.4 +/- 55.9 pg/ml, bFGF 7.3 +/- 3.7 pg/ ml). The serum levels of both VEGF and bFGF were significantly diminished by GT. The level of VEGF dropped from 329.4 +/- 125.5 pg/ml before GT to 278.5 +/- 109.9 pg/ml after GT (P = 0.0042) and the level of bFGF fell from 10.2 +/- 5.04 to 7.78 +/- 4.5 pg/ml (P = 0.019). Comparing to healthy controls, the serum level of bFGF in psoriasis patients was normalised (P = 0.5723) after GT. In contrast, the serum level of VEGF remained significantly increased in psoriasis patients after GT in comparison with healthy blood donors (P = 0.0319). In conclusion, we found that the angiogenic potential which is abnormally increased in patients with psoriasis is significantly alleviated by GT.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a dehet uhelný $x terapeutické užití $7 D003033
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblastový růstový faktor 2 $x krev $7 D016222
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a patologická angiogeneze $x patofyziologie $x terapie $7 D009389
650    _2
$a psoriáza $x patofyziologie $x terapie $7 D011565
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a kůže $x krevní zásobení $7 D012867
650    _2
$a ultrafialové záření $7 D014466
650    _2
$a terapie ultrafialovými paprsky $7 D014467
650    _2
$a vaskulární endoteliální růstový faktor A $x krev $7 D042461
650    _2
$a financování organizované $7 D005381
700    1_
$a Borská, Lenka $7 nlk20060173900
700    1_
$a Pohl, David $7 xx0104099
700    1_
$a Fiala, Zdeněk, $d 1955- $7 nlk19990073147
700    1_
$a Hamáková, Květoslava $7 xx0064204
700    1_
$a Krejsek, Jan, $d 1958- $7 nlk19990073429
773    0_
$t Archives of Dermatological Research $w MED00009242 $g Roč. 298, č. 10 (2007), s. 479-483 $x 0340-3696
910    __
$a ABA008 $b x $y 8
990    __
$a 20100519111533 $b ABA008
991    __
$a 20130815102338 $b ABA008
999    __
$a ok $b bmc $g 724065 $s 587198
BAS    __
$a 3
BMC    __
$a 2007 $b 298 $c 10 $d 479-483 $i 0340-3696 $m Archives of dermatological research $n Arch Dermatol Res $x MED00009242
GRA    __
$a NR8154 $p MZ0
LZP    __
$a 2010-B2/dkme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...